argenx SE (NASDAQ:ARGX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of argenx SE (NASDAQ:ARGX) have earned a consensus rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $658.39.

Several brokerages recently commented on ARGX. JMP Securities lifted their price target on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $717.00 target price (up previously from $670.00) on shares of argenx in a research report on Tuesday, January 14th. JPMorgan Chase & Co. upped their target price on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Baird R W lowered argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and increased their price objective for the company from $439.00 to $715.00 in a report on Tuesday, November 5th.

argenx Trading Down 0.0 %

argenx stock opened at $646.45 on Tuesday. The stock has a market cap of $39.28 billion, a P/E ratio of -734.60 and a beta of 0.58. The company has a fifty day simple moving average of $637.69 and a 200-day simple moving average of $578.86. argenx has a 12-month low of $349.86 and a 12-month high of $678.21.

Hedge Funds Weigh In On argenx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stifel Financial Corp lifted its holdings in shares of argenx by 15.3% in the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock valued at $4,788,000 after buying an additional 1,170 shares during the period. FMR LLC lifted its holdings in argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares during the period. Simplify Asset Management Inc. boosted its position in shares of argenx by 64.0% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock worth $1,311,000 after purchasing an additional 944 shares in the last quarter. Ritholtz Wealth Management grew its stake in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock worth $552,000 after purchasing an additional 414 shares during the period. Finally, Westfield Capital Management Co. LP purchased a new position in shares of argenx in the 3rd quarter valued at about $571,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.